Results 31 to 40 of about 17,128 (260)
Expert Review of Gastroenterology & HepatologyMetabolic dysfunction – associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease (CLD) globally, with increasing prevalence and risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality.
openaire +2 more sources
The Value of TyG‐Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD
Canadian Journal of Gastroenterology and HepatologyBackground: Triglyceride glucose (TyG) and its related index (TyG‐body mass index, TyG‐BMI) are recognized as markers for nonalcoholic fatty liver disease (NAFLD), but their associations with metabolic dysfunction‐associated steatotic liver disease (MASLD) and significant liver fibrosis (SLF) risk are less ...
Haoxuan Zou +3 more
openaire +3 more sources
Dysfunctional VLDL metabolism in MASLD [PDF]
npj Metabolic Health and DiseaseAbstractLipidomics has unveiled the intricate human lipidome, emphasizing the extensive diversity within lipid classes in mammalian tissues critical for cellular functions. This diversity poses a challenge in maintaining a delicate balance between adaptability to recurring physiological changes and overall stability.
Urko M. Marigorta +3 more
openaire +4 more sources
New therapeutic options for metabolic‐associated steatotic liver disease
British Journal of Clinical Pharmacology, EarlyView.An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza +12 more
wiley +1 more source
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials [PDF]
Clinical and Molecular Hepatology, 2023 Ming-Lun Yeh, Ming-Lung Yu
doaj +1 more source
Economic evaluations of antiobesity medications: A systematic literature review
British Journal of Clinical Pharmacology, EarlyView.The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković +5 more
wiley +1 more source
Adding to the confusion in more than just the name [PDF]
Clinical and Molecular Hepatology, 2023 Jacob George
doaj +1 more source
Updated mechanisms of MASLD pathogenesis
Lipids in Health and DiseaseAbstractMetabolic dysfunction-associated steatotic liver disease (MASLD) has garnered considerable attention globally. Changing lifestyles, over-nutrition, and physical inactivity have promoted its development. MASLD is typically accompanied by obesity and is strongly linked to metabolic syndromes.
Yuxuan Li +5 more
openaire +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo +4 more
wiley +1 more source